CY2019004I1 - Τροποποιημενα αντισωματα αντι-ιl-23ρ19 - Google Patents

Τροποποιημενα αντισωματα αντι-ιl-23ρ19

Info

Publication number: CY2019004I1
Authority: CY; Cyprus
Prior art keywords: antibodies; modified anti; modified
Prior art date: 2007-02-23

Application number

CY2019004C

Other languages

English (en)

Other versions

CY2019004I2 (el

Original Assignee

Merck Sharp & Dohme Corp.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-23

Filing date

2019-01-14

Publication date

2019-11-27

2019-01-14 Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.

2019-11-27 Publication of CY2019004I2 publication Critical patent/CY2019004I2/el

2019-11-27 Publication of CY2019004I1 publication Critical patent/CY2019004I1/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)

CY2019004C 2007-02-23 2019-01-14 Τροποποιημενα αντισωματα αντι-ιl-23ρ19 CY2019004I1 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89140907P	2007-02-23	2007-02-23
PCT/US2008/002333 WO2008103432A1 (en)	2007-02-23	2008-02-21	Engineered anti-il-23p19 antibodies

Publications (2)

Publication Number	Publication Date
CY2019004I2 CY2019004I2 (el)	2019-11-27
CY2019004I1 true CY2019004I1 (el)	2019-11-27

Family

ID=39592753

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20121100644T CY1112912T1 (el)	2007-02-23	2012-07-20	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY2019004C CY2019004I1 (el)	2007-02-23	2019-01-14	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY20191100082T CY1121327T1 (el)	2007-02-23	2019-01-21	Τροποποιημενα αντισωματα anti-il-23p19

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20121100644T CY1112912T1 (el)	2007-02-23	2012-07-20	Τροποποιημενα αντισωματα αντι-ιl-23ρ19

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY20191100082T CY1121327T1 (el)	2007-02-23	2019-01-21	Τροποποιημενα αντισωματα anti-il-23p19

Country Status (30)

Country	Link
US (3)	US8293883B2 (el)
EP (2)	EP2426144B1 (el)
JP (5)	JP2010518856A (el)
KR (1)	KR101520110B1 (el)
CN (1)	CN101687925B (el)
AR (1)	AR065420A1 (el)
AT (1)	ATE554791T1 (el)
AU (1)	AU2008218968B2 (el)
BR (1)	BRPI0807710B1 (el)
CA (1)	CA2678749C (el)
CY (3)	CY1112912T1 (el)
DK (2)	DK2059534T3 (el)
ES (2)	ES2708988T3 (el)
FR (1)	FR18C1051I2 (el)
HR (2)	HRP20120611T1 (el)
HU (2)	HUE042172T2 (el)
IL (1)	IL200560A (el)
LT (2)	LT2426144T (el)
LU (1)	LUC00092I2 (el)
MX (1)	MX2009009079A (el)
NL (1)	NL300959I2 (el)
NO (1)	NO2018040I1 (el)
NZ (1)	NZ579158A (el)
PL (2)	PL2059534T3 (el)
PT (2)	PT2426144T (el)
RS (2)	RS52345B (el)
SI (2)	SI2426144T1 (el)
TR (1)	TR201821029T4 (el)
WO (1)	WO2008103432A1 (el)
ZA (1)	ZA200906224B (el)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1896073B1 (en)	2005-06-30	2013-03-06	Janssen Biotech, Inc.	Anti-il-23 antibodies, compositions, methods and uses
US7910703B2 (en)	2006-03-10	2011-03-22	Zymogenetics, Inc.	Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007114319A1 (ja)	2006-03-31	2007-10-11	Chugai Seiyaku Kabushiki Kaisha	抗体の血中動態を制御する方法
JP5043008B2 (ja)	2006-06-08	2012-10-10	中外製薬株式会社	炎症性疾患の予防または治療剤
CA2655372A1 (en)	2006-06-13	2007-12-21	Zymogenetics, Inc.	Il-17 and il-23 antagonists and methods of using the same
TWI426918B (zh)	2007-02-12	2014-02-21	Merck Sharp & Dohme	Ｉｌ-２３拮抗劑於治療感染之用途
DK2059534T3 (da)	2007-02-23	2012-08-06	Merck Sharp & Dohme	Gensplejsede anti-il-23p19-antistoffer
EP2064242A1 (en)	2007-02-23	2009-06-03	Schering Corporation	Engineered anti-il-23p19 antibodies
SI2769729T1 (sl)	2007-09-04	2019-06-28	Compugen Ltd.	Polipeptidin in polinukleotidi in njihove uporabe kot tarča zdravila za izdelavo zdravil in bioloških zdravil
EP3127921A1 (en)	2007-09-26	2017-02-08	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substition in cdr
CN101874041B (zh)	2007-09-26	2013-06-19	中外制药株式会社	抗体恒定区修饰体
WO2009072598A1 (ja)	2007-12-05	2009-06-11	Chugai Seiyaku Kabushiki Kaisha	掻痒症治療剤
TWI548418B (zh)	2007-12-05	2016-09-11	Chugai Pharmaceutical Co Ltd	Anti-NR10 / IL-31RA antibody and its use
EP2708559B1 (en)	2008-04-11	2018-03-28	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2734919C (en)	2008-08-27	2016-08-16	Schering Corporation	Lyophilized formulations of engineered anti-il-23p19 antibodies
JP2012507723A (ja) *	2008-11-03	2012-03-29	シェーリングコーポレイション	炎症性腸疾患生物マーカーおよび関連治療方法
KR20160062207A (ko) *	2008-12-05	2016-06-01	추가이 세이야쿠 가부시키가이샤	항ｎｒ１０ 항체 및 그의 이용
JP5139517B2 (ja) *	2008-12-05	2013-02-06	中外製薬株式会社	抗ｎｒ１０抗体、およびその利用
US20110250644A1 (en) *	2008-12-19	2011-10-13	Schering Corporation	Feed supplement for mammalian cell culture and methods of use
KR101048593B1 (ko)	2009-02-27	2011-07-12	씨제이제일제당 (주)	메칠머캅탄과 디메칠설파이드의 혼합물을 사용하여 메치오닌 생산능을 증가시키는 방법
KR101164711B1 (ko)	2009-02-27	2012-07-11	씨제이제일제당 (주)	미네랄 첨가와 산처리를 이용하여 메치오닌의 용해도를 증가시키는 방법
JP2010210772A (ja) *	2009-03-13	2010-09-24	Dainippon Screen Mfg Co Ltd	液晶表示装置の製造方法
EP3674317B1 (en)	2009-03-19	2024-12-11	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variant
WO2010107110A1 (ja)	2009-03-19	2010-09-23	中外製薬株式会社	抗体定常領域改変体
EP2456787A4 (en) *	2009-07-24	2013-01-30	Univ Leland Stanford Junior	CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE
US8283152B2 (en)	2009-08-28	2012-10-09	Cj Cheiljedang Corporation	Microorganism producing O-acetyl-homoserine and the method of producing O-acetyl-homoserine using the microorganism
US8609396B2 (en)	2009-08-28	2013-12-17	Cj Cheiljedang Corporation	Microorganism producing O-acetyl-homoserine and the method of producing O-acetyl-homoserine using the microorganism
US9301997B2 (en)	2009-09-21	2016-04-05	Peptinov Sas	Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
JO3244B1 (ar)	2009-10-26	2018-03-08	Amgen Inc	بروتينات ربط مستضادات il – 23 البشرية
CN102762591A (zh) *	2010-02-18	2012-10-31	百时美施贵宝公司	结合il-23的基于纤连蛋白的支架结构域蛋白质
PT2635601T (pt)	2010-11-04	2016-09-27	Boehringer Ingelheim Int	Anticorpos anti-il-23
TWI654204B (zh)	2010-11-30	2019-03-21	中外製藥股份有限公司	具有鈣依存性的抗原結合能力之抗體
DE112012000404T5 (de)	2011-01-04	2014-04-17	Charitè Universitätsmedizin Berlin	Modulatoren von IL-12 und/oder IL-23 zur Prävention oder Behandlung des Morbus Alzheimer
EP2726503B1 (en)	2011-06-30	2019-09-04	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP2583979B1 (en) *	2011-10-19	2015-12-16	Effimune	Methods to prepare antibodies directed against p19 subunit of human IL-23
EP2756093A4 (en)	2012-02-01	2015-07-01	Compugen Ltd	C10RF32 ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
CN104507497B (zh) *	2012-05-03	2018-10-19	勃林格殷格翰国际有限公司	抗IL-23p19抗体
WO2014004436A2 (en)	2012-06-27	2014-01-03	Merck Sharp & Dohme Corp.	Crystalline anti-human il-23 antibodies
US10526384B2 (en)	2012-11-19	2020-01-07	Pieris Pharmaceuticals Gmbh	Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
CZ304514B6 (cs)	2012-11-23	2014-06-11	Biotechnologický Ústav Av Čr, V.V.I.	Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23
US20150307606A1 (en) *	2012-12-13	2015-10-29	Ashwin Basarkar	Lyophilized spherical pellets of anti-il-23 antibodies
UA117466C2 (uk)	2012-12-13	2018-08-10	Мерк Шарп Енд Доме Корп.	СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JOP20140049B1 (ar) *	2013-03-08	2021-08-17	Lilly Co Eli	أجسام مضادة ترتبط بـ il-23
AP2015008801A0 (en)	2013-03-15	2015-10-31	Amgen Inc	Methods for treating crohn's disease using an anti-il23 antibody
CN105209064A (zh)	2013-03-15	2015-12-30	美国安进公司	使用抗il-23抗体治疗银屑病的方法
HRP20211911T1 (hr)	2013-03-15	2022-03-18	Protagonist Therapeutics, Inc.	Analozi hepcidina i njihova uporaba
EP3960754A3 (en)	2014-05-16	2022-07-06	Protagonist Therapeutics, Inc.	Alpha4beta7 integrin thioether peptide antagonists
EP3789397B1 (en)	2014-05-22	2023-12-06	Pieris Pharmaceuticals GmbH	Novel specific-binding polypeptides and uses thereof
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
AU2015289642B2 (en)	2014-07-17	2021-02-25	Protagonist Therapeutics, Inc.	Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3172339A1 (en)	2014-07-24	2017-05-31	Boehringer Ingelheim International GmbH	Biomarkers useful in the treatment of il-23a related diseases
JP6920194B2 (ja) *	2014-08-19	2021-08-18	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗ｔｉｇｉｔ抗体
SG11201701423RA (en)	2014-09-03	2017-03-30	Boehringer Ingelheim Int	Compound targeting il-23a and tnf-alpha and uses thereof
US10301371B2 (en)	2014-10-01	2019-05-28	Protagonist Therapeutics, Inc.	Cyclic monomer and dimer peptides having integrin antagonist activity
MX391184B (es)	2014-10-01	2025-03-19	Protagonist Therapeutics Inc	ANTAGONISTAS DE MONOMÉRICOS Y DIMÉRICOS PEPTÍDICOS DE a4ß7 NOVEDOSOS.
AR102417A1 (es)	2014-11-05	2017-03-01	Lilly Co Eli	Anticuerpos biespecíficos anti-tnf- / anti-il-23
JP6758304B2 (ja)	2015-02-04	2020-09-23	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	炎症性疾患の処置法
CA2977534A1 (en)	2015-04-14	2016-10-20	Boehringer Ingelheim International Gmbh	Methods of treating diseases
AU2016248786B2 (en)	2015-04-14	2022-01-20	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing lL-31 antagonist as active ingredient
HUE072989T2 (hu)	2015-04-14	2025-12-28	Chugai Pharmaceutical Co Ltd	Gyógyszerkészítmény atópiás dermatitis megelõzésére és/vagy kezelésére, mely hatóanyagként IL-31 antagonistát tartalmaz
US10787490B2 (en)	2015-07-15	2020-09-29	Protaganist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017049035A1 (en)	2015-09-17	2017-03-23	Amgen Inc.	Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
TWI811716B (zh)	2015-09-18	2023-08-11	德商百靈佳殷格翰國際股份有限公司	治療發炎性疾病之方法
CN108472367A (zh)	2015-12-22	2018-08-31	美国安进公司	作为对il23拮抗剂的临床应答的预测因子的ccl20
CA3009834A1 (en)	2015-12-30	2017-07-06	Protagonist Therapeutics, Inc.	Analogues of hepcidin mimetics with improved in vivo half lives
US10407468B2 (en)	2016-03-23	2019-09-10	Protagonist Therapeutics, Inc.	Methods for synthesizing α4β7 peptide antagonists
EP3443005A1 (en)	2016-04-15	2019-02-20	Boehringer Ingelheim International GmbH	Methods of treating inflammatory diseases
JP2019530707A (ja)	2016-10-10	2019-10-24	セレラントセラピューティクスインコーポレイテッド	イソキノリジノベンゾジアゼピン（ｉｑｂ）−１（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール（ｃｂｉ）二量体
WO2018071504A2 (en)	2016-10-14	2018-04-19	Boehringer Ingelheim International Gmbh	Methods of treating diseases
CA3084459A1 (en)	2016-10-16	2018-04-19	Cellerant Therapeutics, Inc.	Anti-il1-rap antibodies
WO2018071910A2 (en) *	2016-10-16	2018-04-19	Cellerant Therapeutics, Inc.	Anti-il1-rap antibodies
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja)	2017-05-02	2023-11-16	メルク・シャープ・アンド・ドーム・エルエルシー	抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
EP3681900A4 (en)	2017-09-11	2021-09-08	Protagonist Therapeutics, Inc.	OPIOID AGONIST PEPTIDES AND THEIR USES
EP4501952A3 (en)	2018-02-08	2025-04-16	Protagonist Therapeutics, Inc.	Conjugated hepcidin mimetics
TWI744617B (zh)	2018-03-30	2021-11-01	美商美國禮來大藥廠	治療潰瘍性結腸炎之方法
KR20210032441A (ko)	2018-07-13	2021-03-24	아스트라제네카 콜라보레이션 벤처스, 엘엘씨	브라지쿠맙을 이용한 궤양성 대장염의 치료
KR20210089215A (ko)	2018-11-07	2021-07-15	머크 샤프 앤드 돔 코포레이션	항-lag3 항체 및 항-pd-1 항체의 공동-제제
WO2020108530A1 (zh)	2018-11-27	2020-06-04	信达生物制药(苏州)有限公司	抗IL-23p19抗体及其用途
MA55585A (fr)	2019-04-12	2022-02-16	Almirall Sa	Procédé de traitement du psoriasis en plaques résistant aux esters d'acide fumarique
KR20210140780A (ko) *	2019-04-15	2021-11-23	썬 파마슈티칼 인더스트리스 리미티드	건선성 관절염 대상체의 치료 방법
CA3146390A1 (en)	2019-07-10	2021-01-14	Protagonist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
BR112022006590A2 (pt)	2019-11-20	2022-06-28	Chugai Pharmaceutical Co Ltd	Preparação contendo anticorpos
AU2020409124A1 (en)	2019-12-20	2022-06-30	Novarock Biotherapeutics, Ltd.	Anti-interleukin-23 p19 antibodies and methods of use thereof
US12018057B2 (en)	2020-01-15	2024-06-25	Janssen Biotech, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TWI882061B (zh)	2020-01-15	2025-05-01	美商健生生物科技公司	介白素-23受體之肽抑制劑及其治療發炎性疾病之用途
WO2021201276A1 (ja)	2020-04-03	2021-10-07	株式会社メドレックス	Ｉｌ－２３発現を特異的に抑制する二本鎖ｒｎａおよびそれを含む医薬組成物
KR102481026B1 (ko) *	2020-04-22	2022-12-22	한양대학교 산학협력단	인터루킨 23의 항체를 포함하는 화학요법유발 말초신경병증의 예방 또는 치료용 약학적 조성물
CN112807428B (zh) *	2020-06-12	2024-08-27	江苏荃信生物医药股份有限公司	包含抗人白介素23单克隆抗体的药物组合物
AR123477A1 (es)	2020-09-10	2022-12-07	Lilly Co Eli	Formulaciones de anticuerpos terapéuticos
PE20240631A1 (es)	2020-11-20	2024-03-26	Janssen Pharmaceutica Nv	Composiciones de inhibidores peptidicos del receptor de interleucina-23
JP2024521748A (ja)	2021-05-28	2024-06-04	イーライリリーアンドカンパニー	潰瘍性大腸炎に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体調節
EP4370146A4 (en)	2021-07-14	2025-05-21	Janssen Biotech, Inc.	Lipidated peptide inhibitors of the interleukin-23 receptor
US20240391994A1 (en)	2021-09-30	2024-11-28	Eli Lilly And Company	Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
CN117916273A (zh) *	2021-09-30	2024-04-19	江苏恒瑞医药股份有限公司	抗il23抗体融合蛋白及用途
WO2023144699A1 (en)	2022-01-25	2023-08-03	Sun Pharmaceutical Industries Limited	Methods for treatment of subjects with plaque psoriasis of the scalp
WO2024077113A1 (en)	2022-10-06	2024-04-11	Eli Lilly And Company	Methods of treating fatigue in ulcerative colitis
CN120882881A (zh)	2023-02-22	2025-10-31	伊莱利利公司	溃疡性结肠炎的基因调控及其用途
AU2024277083A1 (en) *	2023-05-25	2025-12-11	Sun Pharmaceutical Industries Limited	Methods and compositions for treating plaque psoriasis
WO2025083549A1 (en)	2023-10-16	2025-04-24	Sun Pharma Advanced Research Company Limited	Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
WO2025109545A1 (en)	2023-11-23	2025-05-30	Sun Pharmaceutical Industries Limited	Methods for producing recombinant proteins
WO2025117506A1 (en)	2023-11-29	2025-06-05	Gilead Sciences, Inc.	Therapies for the treatment of inflammatory bowel disease
WO2025120601A1 (en)	2023-12-06	2025-06-12	Sun Pharmaceutical Industries Limited	Methods and compositions for treating nail psoriasis

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) *	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en)	1990-01-19	1991-07-24	Merck & Co. Inc.	Method for producing recombinant immunoglobuline
ATE297465T1 (de)	1991-11-25	2005-06-15	Enzon Inc	Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US6096289A (en) *	1992-05-06	2000-08-01	Immunomedics, Inc.	Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
PT1589107E (pt)	1992-08-21	2010-03-29	Univ Bruxelles	Imunoglobulinas desprovidas de cadeias leves
US6005079A (en)	1992-08-21	1999-12-21	Vrije Universiteit Brussels	Immunoglobulins devoid of light chains
WO1994025591A1 (en)	1993-04-29	1994-11-10	Unilever N.V.	PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5888530A (en)	1995-07-21	1999-03-30	The General Hospital Corporation	Method of enhancing delivery of a pharmaceutical formulation
US6060284A (en) *	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
WO1999054357A1 (en) *	1998-04-14	1999-10-28	Chugai Research Institute For Molecular Medicine, Inc.	Novel cytokine-like protein
US6326482B1 (en)	1999-04-23	2001-12-04	Genentech, Inc.	SH2 domain-containing peptides
CA2366706A1 (en)	1999-03-11	2000-09-14	Schering Corporation	Mammalian cytokines; related reagents and methods
KR100894359B1 (ko)	1999-09-09	2009-04-22	쉐링 코포레이션	포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법
US7090847B1 (en) *	1999-09-09	2006-08-15	Schering Corporation	Mammalian cytokines; related reagents and methods
US7422743B2 (en) *	2000-05-10	2008-09-09	Schering Corporation	Mammalian receptor protein DCRS5;methods of treatment
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US20040014194A1 (en)	2002-03-27	2004-01-22	Schering Corporation	Beta-secretase crystals and methods for preparing and using the same
US20070134247A9 (en)	2002-04-12	2007-06-14	Ramot At Tel Aviv University Ltd.	Prevention of brain inflammation as a result of induced autoimmune response
EP2108660A1 (en)	2002-10-30	2009-10-14	Genentech, Inc.	Inhibition of IL-17 production
WO2004071517A2 (en)	2003-02-06	2004-08-26	Schering Corporation	Uses of il-23 related reagents
CA2518262C (en)	2003-03-10	2014-05-06	Schering Corporation	Uses of il-23 agonists and antagonists; related reagents
US7410483B2 (en)	2003-05-23	2008-08-12	Novare Surgical Systems, Inc.	Hand-actuated device for remote manipulation of a grasping tool
WO2005044853A2 (en)	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
DK1678314T3 (da)	2003-10-22	2012-12-03	Keck Graduate Inst	Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
CA2545756A1 (en)	2003-11-07	2005-05-26	Curagen Corporation	Antibodies against secretoryleukocyte protease inhibitor
AR046833A1 (es)	2003-11-10	2005-12-28	Schering Corp	Anticuerpos anti-interleuquina-10
DE602005022871D1 (de)	2004-06-07	2010-09-23	Univ Ramot	Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
AR049390A1 (es) *	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP2292758A3 (en) *	2004-12-20	2013-12-25	Merck Sharp & Dohme Corp.	Uses of mammalian cytokine; related reagents
ES2905923T3 (es) *	2005-02-08	2022-04-12	Genzyme Corp	Anticuerpos de TGFbeta
EP1896073B1 (en) *	2005-06-30	2013-03-06	Janssen Biotech, Inc.	Anti-il-23 antibodies, compositions, methods and uses
JP5022367B2 (ja) *	2005-08-25	2012-09-12	イーライリリーアンドカンパニー	抗ｉｌ−２３抗体
JP5350793B2 (ja)	2005-08-31	2013-11-27	メルク・シャープ・アンド・ドーム・コーポレーション	改変抗ｉｌ−２３抗体
SI2548577T1 (sl)	2005-12-29	2017-05-31	Janssen Biotech, Inc.	Človeška protitelesa proti il-23, sestavki, postopki in uporabe
CA2655372A1 (en) *	2006-06-13	2007-12-21	Zymogenetics, Inc.	Il-17 and il-23 antagonists and methods of using the same
DK2059534T3 (da) *	2007-02-23	2012-08-06	Merck Sharp & Dohme	Gensplejsede anti-il-23p19-antistoffer
EP2064242A1 (en) *	2007-02-23	2009-06-03	Schering Corporation	Engineered anti-il-23p19 antibodies
EP2150564A2 (en)	2007-04-27	2010-02-10	ZymoGenetics, Inc.	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
AR068723A1 (es) *	2007-10-05	2009-12-02	Glaxo Group Ltd	Proteina que se une a antigenos que se une a il-23 humana y sus usos
US8975382B2 (en)	2007-11-27	2015-03-10	Ablynx N.V.	Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009082624A2 (en)	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonists of il-17a, il-17f, and il-23 and methods of using the same

2008
- 2008-02-21 DK DK08714211.3T patent/DK2059534T3/da active
- 2008-02-21 HR HRP20120611AT patent/HRP20120611T1/hr unknown
- 2008-02-21 HU HUE11172014A patent/HUE042172T2/hu unknown
- 2008-02-21 PL PL08714211T patent/PL2059534T3/pl unknown
- 2008-02-21 SI SI200832032T patent/SI2426144T1/sl unknown
- 2008-02-21 LT LTEP11172014.0T patent/LT2426144T/lt unknown
- 2008-02-21 ES ES11172014T patent/ES2708988T3/es active Active
- 2008-02-21 SI SI200830700T patent/SI2059534T1/sl unknown
- 2008-02-21 AT AT08714211T patent/ATE554791T1/de active
- 2008-02-21 PT PT11172014T patent/PT2426144T/pt unknown
- 2008-02-21 RS RS20120308A patent/RS52345B/sr unknown
- 2008-02-21 EP EP11172014.0A patent/EP2426144B1/en active Active
- 2008-02-21 KR KR1020097019349A patent/KR101520110B1/ko active Active
- 2008-02-21 WO PCT/US2008/002333 patent/WO2008103432A1/en not_active Ceased
- 2008-02-21 EP EP08714211A patent/EP2059534B1/en active Active
- 2008-02-21 AU AU2008218968A patent/AU2008218968B2/en active Active
- 2008-02-21 CN CN2008800131689A patent/CN101687925B/zh active Active
- 2008-02-21 US US12/526,543 patent/US8293883B2/en active Active
- 2008-02-21 DK DK11172014.0T patent/DK2426144T3/en active
- 2008-02-21 PT PT08714211T patent/PT2059534E/pt unknown
- 2008-02-21 AR ARP080100715A patent/AR065420A1/es active IP Right Grant
- 2008-02-21 NZ NZ579158A patent/NZ579158A/en unknown
- 2008-02-21 JP JP2009550920A patent/JP2010518856A/ja active Pending
- 2008-02-21 RS RS20181559A patent/RS58098B1/sr unknown
- 2008-02-21 CA CA2678749A patent/CA2678749C/en active Active
- 2008-02-21 PL PL11172014T patent/PL2426144T3/pl unknown
- 2008-02-21 MX MX2009009079A patent/MX2009009079A/es active IP Right Grant
- 2008-02-21 ES ES08714211T patent/ES2388837T3/es active Active
- 2008-02-21 TR TR2018/21029T patent/TR201821029T4/tr unknown
- 2008-02-21 BR BRPI0807710-0A patent/BRPI0807710B1/pt active IP Right Grant
2009
- 2009-08-23 IL IL200560A patent/IL200560A/en active Protection Beyond IP Right Term
- 2009-09-08 ZA ZA200906224A patent/ZA200906224B/xx unknown
2011
- 2011-02-21 US US13/031,544 patent/US8404813B2/en active Active
2012
- 2012-03-07 JP JP2012050650A patent/JP5014521B2/ja active Active
- 2012-07-10 JP JP2012154567A patent/JP2012228259A/ja active Pending
- 2012-07-20 CY CY20121100644T patent/CY1112912T1/el unknown
- 2012-12-17 US US13/717,131 patent/US9809648B2/en active Active
2014
- 2014-02-27 JP JP2014036399A patent/JP6054898B2/ja active Active
2016
- 2016-10-27 JP JP2016210272A patent/JP2017060482A/ja not_active Withdrawn
2018
- 2018-11-09 HU HUS1800045C patent/HUS1800045I1/hu unknown
- 2018-11-13 LU LU00092C patent/LUC00092I2/fr unknown
- 2018-11-15 NO NO2018040C patent/NO2018040I1/no unknown
- 2018-12-04 FR FR18C1051C patent/FR18C1051I2/fr active Active
- 2018-12-05 NL NL300959C patent/NL300959I2/en unknown
- 2018-12-13 LT LTPA2018015C patent/LTC2059534I2/lt unknown
- 2018-12-21 HR HRP20182174TT patent/HRP20182174T1/hr unknown
2019
- 2019-01-14 CY CY2019004C patent/CY2019004I1/el unknown
- 2019-01-21 CY CY20191100082T patent/CY1121327T1/el unknown

Also Published As

Publication number	Publication date
JP5014521B2 (ja)	2012-08-29
BRPI0807710A8 (pt)	2016-02-10
EP2059534A1 (en)	2009-05-20
SI2059534T1 (sl)	2012-08-31
KR20090114459A (ko)	2009-11-03
US20110142853A1 (en)	2011-06-16
ZA200906224B (en)	2010-07-28
ATE554791T1 (de)	2012-05-15
AU2008218968A1 (en)	2008-08-28
LT2426144T (lt)	2018-12-10
JP2014128278A (ja)	2014-07-10
MX2009009079A (es)	2009-08-31
JP2017060482A (ja)	2017-03-30
CN101687925B (zh)	2012-10-31
AU2008218968B2 (en)	2013-10-17
US9809648B2 (en)	2017-11-07
CY2019004I2 (el)	2019-11-27
ES2388837T3 (es)	2012-10-19
CY1112912T1 (el)	2016-04-13
PL2059534T3 (pl)	2012-09-28
TR201821029T4 (tr)	2019-01-21
IL200560A0 (en)	2010-05-17
EP2426144B1 (en)	2018-10-31
NO2018040I1 (no)	2018-11-15
BRPI0807710A2 (pt)	2014-05-27
RS52345B (sr)	2012-12-31
US8404813B2 (en)	2013-03-26
CA2678749A1 (en)	2008-08-28
PT2426144T (pt)	2019-02-06
HUS1800045I1 (hu)	2018-12-28
US8293883B2 (en)	2012-10-23
DK2059534T3 (da)	2012-08-06
ES2708988T3 (es)	2019-04-12
FR18C1051I1 (el)	2019-02-15
SI2426144T1 (sl)	2019-02-28
US20100272731A1 (en)	2010-10-28
PT2059534E (pt)	2012-07-17
CY1121327T1 (el)	2020-05-29
FR18C1051I2 (fr)	2019-12-27
RS58098B1 (sr)	2019-02-28
AR065420A1 (es)	2009-06-03
HUE042172T2 (hu)	2019-06-28
CN101687925A (zh)	2010-03-31
JP2010518856A (ja)	2010-06-03
DK2426144T3 (en)	2019-01-07
WO2008103432A1 (en)	2008-08-28
HRP20182174T1 (hr)	2019-02-22
NL300959I2 (en)	2019-01-15
LTPA2018015I1 (lt)	2019-01-10
KR101520110B1 (ko)	2015-05-18
JP2012228259A (ja)	2012-11-22
JP2012135319A (ja)	2012-07-19
NZ579158A (en)	2012-01-12
HRP20120611T1 (hr)	2012-10-31
EP2426144A1 (en)	2012-03-07
PL2426144T3 (pl)	2019-05-31
BRPI0807710B1 (pt)	2021-12-14
US20130122009A1 (en)	2013-05-16
LTC2059534I2 (lt)	2019-10-10
LUC00092I1 (el)	2018-11-15
LUC00092I2 (el)	2019-12-24
CA2678749C (en)	2018-03-13
JP6054898B2 (ja)	2016-12-27
IL200560A (en)	2013-11-28
HK1127864A1 (en)	2009-10-09
EP2059534B1 (en)	2012-04-25

Publication	Publication Date	Title
CY2019004I2 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
IL212175B (en)	2019-08-29	Muc1* antibodies
PL3059246T3 (pl)	2018-11-30	Zmodyfikowany region stały przeciwciała
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
BRPI0809677A2 (pt)	2014-10-07	Anticorpos anti-ige
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
EP2211903A4 (en)	2011-07-06	CLL-1 ANTIBODY
BRPI0819165A2 (pt)	2015-06-23	Anticorpos anti-vegf
DK2131860T3 (da)	2014-01-13	Anti-sclerostin-antistoffer
HRP20170963T1 (hr)	2017-09-22	Modificirani saharidi
PT2195026E (pt)	2014-03-31	Anticorpos anti-esclerostina
BRPI0820073A2 (pt)	2015-06-23	Anticorpos anti-axl
DK3118221T3 (da)	2019-09-23	Proteiner
PT2173888T (pt)	2016-11-17	Resumo
BRPI0807991A2 (pt)	2014-06-17	Anticorpos anti-il-23r elaborados.
HUE038501T2 (hu)	2018-10-29	Antitest készítmények
BRPI0821573A2 (pt)	2016-08-09	benzofuropirimidonas
EP2172483A4 (en)	2010-08-04	ANTI-MUC17 ANTIBODY
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
BRPI0815567A2 (pt)	2015-02-18	Anticorpos híbridos antialfa v-integrina projetados
EP2207803A4 (en)	2010-11-24	Cd9-specific human antibodies
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
BRPI0814971A2 (pt)	2015-02-03	Proteína